Fig. 2.
![Fig. 2. Distribution of the duration of neutropenia in patients of group A with prophylactic inhalations (○) and group B without prophylactic inhalations (•). For patients with proven, probable, or possible IA, the number of neutropenic days until an IA infection was suspected or proven are marked with squares ([□] in group A and [▪] in group B).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/93/11/10.1182_blood.v93.11.3654/4/blod41111002x.jpeg?Expires=1735551644&Signature=eEV35rYO6QoTWwsEN4uEi-E-KFbds-ixGzN6EsKy7Bi~3muGiL7~rPSYRDmiGV3yGBOWYyfa6vVpntwG26NU~G0eDOA69ZTGJhFYZjlQWHZKXHLv7eAcAoO6Z8Yjaj-QcZEkCw0UXCUkkSE0WEiCUSN-fSW0QUwUYynJBEa5I45iAtj4QYdAssZLnAflg-057UXgeHRIphc0Hx5NmpMhXmAP4I2einak9XS26uGpLFqs-Lhtnt~Y5oXUOq6NvXfPmmiij7sXYzkuAxG9fvpdsIBlE8yt3vZKr4BCA2BKxl42SMsjQIKYAL18izPMm1ApatNrsIYxE7Jslc45e5FuyQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Distribution of the duration of neutropenia in patients of group A with prophylactic inhalations (○) and group B without prophylactic inhalations (•). For patients with proven, probable, or possible IA, the number of neutropenic days until an IA infection was suspected or proven are marked with squares ([□] in group A and [▪] in group B).
